Albireo Pharma Inc

NASDAQ:ALBO   3:59:57 PM EDT
31.25
+0.18 (+0.58%)
Products

Albireo Submits For U.S. FDA And EMA Product Approval Of Once-Daily Odevixibat For Pfic

Published: 12/08/2020 21:52 GMT
Albireo Pharma Inc (ALBO) - Albireo Submits for U.S. FDA and Ema Product Approval of Once-daily Odevixibat for Pfic.
Albireo Pharma Inc - FDA Has Granted Odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations.
Albireo Pharma - Ema Grants Accelerated Assessment, Validates Marketing Authorization Application for Odevixibat With Orphan Designation.
Albireo Pharma- Ema Validates Marketing Authorization Application for Odevixibat With Access to Priority Medicines (prime).
Albireo Pharma - Anticipates Potential Regulatory Approvals, Issuance of a Rare Pediatric Disease Priority Review Voucher & Launch in H2 of 2021.
Albireo Pharma Inc - Data on Pfic Types 1, 2, 3 Submitted to Support Use Across a Wide Range of Patients.